anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Lung cancer is the most common cancer worldwide in mortality and the second in incidence. Epidemiological studies found a higher lung cancer risk for smoking women in comparison to men, but these sex differences, irrespective of smoking habits, remain controversial. One of the hypotheses concerns the genetic contribution of the sex chromosomes. However, while genome-wide association studies identified many lung cancer susceptibility loci, these analyses have excluded X-linked loci.
METHODS: To account for nongenetic factors, we first presented an association test based on an additive-multiplicative hazard model accounting for random/nonrandom X-inactivation process. A simulation study was performed to investigate the properties of the proposed test as compared with the Wald test from a Cox model with random X-inactivation process and the partial likelihood ratio test proposed by Xu et al. accounting for nonrandom X-inactivation process. Then, we performed an X chromosome-wide association study on 9,261 individuals from the population-based cohort CARTaGENE to identify susceptibility loci for lung cancer among current and past smokers. We adjusted for the PLCOm2012 lung cancer risk score used in screening programs.
RESULTS: Simulation results show the good behavior of the proposed test in terms of power and type I error probability as compared to the Xu et al. and the Wald test. Using the proposed test statistic and adjusting for the PLCOm2012 score, the X chromosome-wide statistical analysis identified two SNPs in low-linkage disequilibrium located in the IL1RAPL1 (IL-1 R accessory protein-like) gene: rs12558491 (p = 2.75×10-9) and rs12835699 (p = 1.26×10-6). For both SNPs, the minor allele was associated with lower lung cancer risk. Adjusting for multiple testing, no signal was detected using the Wald or the Xu et al. likelihood ratio tests.
CONCLUSION: By taking into account smoking behavior and the X-inactivation process, the investigation of the X chromosome has shed a new light on the association between X-linked loci and lung cancer. We identified two loci associated with lung cancer located in the IL1RAPL1 gene. This finding would have been overlooked by examining only results from other test statistics.
This will be a single dose study. Participants will receive each of the two following treatments of HU in a randomized, crossover fashion: Either approximately 20 mg/kg/day (rounded to the nearest 200mg and no greater than 30 mg/kg) or the participant's usual daily dose as: 1) a liquid containing 100 mg/mL of hydroxyurea, or 2) Droxia® 200 mg capsules administered orally.
People with CKD 4 (eGFR 15-29). They will have body composition measured, and eGFR measured.
The invention discloses an edible and applicable ingredient produced through multiple methods and forms. The ingredient is applied by customers in a convenient, effective and efficient manner. The edible and applicable ingredient comprises at least one of plant ingredients, Chinese medicaments, nutrient ingredients, health ingredients, clean ingredients and food additives. The ingredient has nutrients, comprising sugar, vitamins, minerals and an antioxidant, and has medicinal value and cleanness function. The ingredient is in the form of peeled, unpeeled, unshelled, cut or uncut extract, juice, sauce, liquid, grease, gel, jelly, wax, cream, paste, powder, flake, small granule, chip and bulker. The ingredient can be uncooked or cooked in the following methods: frying, drying, roasting, baking, steaming, boiling, barbecuing and deep-frying. The ingredient can be added into various fabrics and media.
FIELD: medicine. ^ SUBSTANCE: group of inventions refers to veterinary science. A method for improving xenobiotic deactivation in an animal involves animal feeding with a food composition containing lipoic acid where lipoic acid is found in an amount at least 150 portions/million. A kit applicable for introduction of lipoic acid to the animal comprises in separate containers in a single package or in separate containers in a virtual package as it may be required, at least one lipoic acid in the food composition where lipoic acid is found in the amount at least 150 portions/million and at least one of: (1) one or more ingredients applicable for consumption by animals, (2) instructions to combine lipoic acid and one or more ingredients applicable for consumption by animals for improving xenobiotic deactivation by liver, and (3) instructions to use lipoic acid and one or more ingredients applicable for consumption by animals. The food composition applicable for improving xenobiotic deactivation by liver in animals, contains a life-sustaining amount of nutrients and lipoic acid more than 150 portions/million. ^ EFFECT: group of inventions provides improved liver function in animals. ^ 14 cl, 1 ex, 1 dwg
Subjects will receive oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 under fasted conditions. The study period in which a subject will receive this treatment will be determined by random assignment to 1 of 6 treatment sequences.
Hemodialysis (HD) is a taxing procedure with extensive illness burden and arduous self-care demands. As such, more than 30% of individuals on HD experience elevated symptoms of depression-and, research shows that comorbid depression is associated with adverse kidney disease outcomes, greater risk of hospitalization, and decreased survival rates. Current interventions to treat depressive symptoms in individuals on HD are resource intensive, infrequently administered, and often involve delivery of psychotherapy by highly-trained clinicians via multiple face-to-face communications. There remains a critical scientific gap for easily disseminatable and efficient strategies to improve emotional well-being profiles of individuals on HD in the U.S. and around the world. The objective in this small R01 study is to design a virtual reality (VR) platform that fully immerses users into a fictitious lifelike environment, to deliver an evidence-based positive psychological intervention and to test whether it improves the emotional well-being of individuals on HD with comorbid depression. For instance, during the module focused on mindfulness/meditation, the investigators will use a head-mounted display to fully immerse and transport individuals on HD to an open field beside a calming stream where they will engage in a 12-minute guided meditation. As such, the investigators propose to conduct a 2-arm randomized controlled trial in which individuals on HD (N=84) will be randomly assigned to receive either the JovialityTM VR-based positive psychological intervention or an active control condition (i.e., 2-dimensional wildlife footage and nature-based settings with inert music). The investigators hypothesize that chairside delivery of psychotherapeutic treatment in individuals on HD using a VR environment will prove feasible and will result in significant improvements in depressive symptoms, quality of life, and treatment adherence, with lower evident rates for missed HD sessions and lower hospitalizations-all while serving as a more cost-effective and far- reaching platform that will greatly expand dissemination. Knowledge gained from completion of the proposed research will result in the first VR software application to deliver psychotherapy to HD patients, while simultaneously allowing them to leave the confines of the clinic and virtually travel to distant regions of the world.
The invention discloses a Chinese materia medica preparation for treating borborygmus diarrhoea and a preparation method thereof. The Chinese materia medica preparation comprises the following components: Chinese pulsatilla root, common yam rhizome, stir-fried gordon euryale seed, parslane herb, costus root, nutmeg, largehead atractylodes rhizome, poria, voilet, longstamen onion bulb, areca peel, golden thread and tangerine peel. When the patient also obviously suffers from lumbago, cold intolerance, hypogastric pain and diarrhoea when getting up in the morning, the Chinese materia medica preparation is added with cassia bark, south dodder seed, Chinese magnoliavine fruit and rehmannia glutinosa. When the patient suffers from obvious bellyache, abdominal distension and pain reduction after diarrhoea, the Chinese materia medica preparation is added with officinal magnolia bark, bitter orange, white paeony root, kudzu-vine root and divaricate saposhnikovia root. When the patient suffers from poor appetite and apepsia, the Chinese materia medica preparation is added with charred triplet and chicken's gizzard-membrane. The Chinese materia medica preparation of the invention has effects of calming the liver and relieving pain, regulating Qi and strengthening the spleen, tonifying spleen, lungs and kidney, tonifying middle-Jiao and Qi and lifting yang and relieving diarrhea, mainly treats symptoms of acute and chronic enteritis, colonitis, borborygmus diarrhoea caused by liver-yang hyperactivity and weak spleen and stomach, poor appetite and loose stools, limb tiredness and hypodynamia, pain releasing after diarrhoea, repeated attacks and the like, has simple formula and low manufacturing cost and can be popularized and used.
While direct oral anticoagulants (DOACs) are frequently used to treat venous thromboembolism (VTE), the outcomes of patients with inherited thrombophilia (IT) receiving DOACs for VTE remain understudied. We used data from the international RIETE registry to compare the rates of VTE recurrences, major bleeding, and mortality during anticoagulant treatment in VTE patients with and without IT, grouped by the use of DOACs or standard anticoagulant therapy. Among 103,818 enrolled patients, 21,089 (20.3%) were tested for IT, of whom 8422 (39.9%) tested positive: Protein C deficiency 294, Protein S deficiency 726, Antithrombin deficiency 240, Factor V Leiden 2248, Prothrombin gene mutation 1434, combined IT 3480. Overall, 14,189 RIETE patients (6.2% with IT) received DOACs, and 89,629 standard anticoagulation (8.4% with IT), mostly with heparins followed by vitamin K antagonists. Proportions of patients receiving DOACs did not differ between IT-positive and IT-negative patients. Rates of VTE recurrence on anticoagulant treatment were highest in patients with AT deficiency (P < 0.01). Rates of on-treatment major bleeding and all-cause mortality were lowest among patients with Factor V Leiden (FVL) or PT G20210A mutations, compared with patients who tested negative. Patients with IT who received DOACs had lower rates of major bleeding than those receiving standard anticoagulation. Excluding FVL and Protein S deficiency, patients with IT had lower rates of VTE recurrence with DOACs than with standard anticoagulation. DOACs are equally safe and effective in VTE patients with IT, with lower bleeding rates than those on standard anticoagulation.
PURPOSE: This study evaluated the protective effect of hesperidin on injury induced by gastric ischemia-reperfusion.
METHODS: Fifty male Sprague Dawley rats (250-300 g) were divided into five groups: control (C), sham (S), ischemia (I), ischemia-reperfusion (I/R) and hesperidin + ischemia-reperfusion (Hes + I/R). Hesperidin was injected intraperitoneally at the dose of 100 mg/kg one hour before the experimental stomach ischemia-reperfusion. Celiac artery was ligated. After 45 minutes ischemia and 60 minutes reperfusion period, blood samples were obtained under anesthesia. Then, animals were sacrificed, stomach tissues were excised for biochemical, and histopathological analyses were performed. Malondialdehyde levels and superoxide dismutase, glutathione peroxidase activities and total antioxidant status (TAS), total oxidant status (TOS), protein, total thiol parameters were measured in plasma, and tissue homogenate samples. H + E, periodic acid-Schiff, hypoxia inducible factor, terminal deoxynucleotidyl transferase mediated deoxyuridine triphosphate nick end-labeling (TUNEL), and proliferating cell nuclear antigen (PCNA) for cell proliferation as immunohistochemical parameters were determined.
RESULTS: Upon biochemical and histopathological assessment, hesperidin decreased stomach tissue changes in comparison with IR group. Ischemia-reperfusion injury led to a considerably increase in malondialdehyde, protein, and TOS levels (p < 0.001) in stomach tissue. Hesperidin treatment significantly decreased malondialdehyde, protein, and TOS levels (p < 0.001). Hesperidin increased superoxide dismutase, TAS, total thiol and glutathione peroxidase activities in comparison with IR group. Hesperidin reduced damage and also increased TUNEL and PCNA immunoreactivity in stomach tissue.
CONCLUSIONS: Hesperidin was able to decrease I/R injury of the stomach tissue due to inhibition of lipid peroxidation and protein oxidation, duration of antioxidant, and free radical scavenger properties. Consequently, hesperidin can provide a beneficial therapeutic choice for preventing stomach tissue ischemia-reperfusion injury in clinical application.
FIELD: medicine, oncology. SUBSTANCE: invention relates to treatment of patients with breast cancer at preoperative stage. Invention proposes to administrate chemopreparations based on autoblood at increased course doses in combination with epithalamine based on autoblood by separate route for 4 weeks successively beginning from the 1st day. Vincristine and methotrexate are administrated once per a week up to 1, 2 course doses; fluoro-uracil is dosed 3 times per a week for each other day up to 1, 5 course doses and epithalamine is dosed at the dose 10 mg, 3 times per a week for each other day by drop intravenous route. In other days beginning from the second day epithalamine is administrated at the dose 10 mg by intramuscular route. Method ensures to use enhanced course doses of antitumor preparations at simultaneous improvement of tolerance of chemotherapy course and to correct immunohormonal status. EFFECT: enhanced effectiveness of treatment. 5 tbl, 3 ex
A method for packaging sliced deer antler is provided to prevent the sliced deer antler from sticking to another sliced deer antler without twisting or deforming the sliced deer antler when the sliced deer antler is dried. In a method for packaging sliced deer antler, a lower conveyor belt(20) is rotated between a drive shaft and a rotational shaft. An upper conveyor belt(30) is installed on the upper side of the lower conveyor belt side by side and is rotated in the opposite direction to the lower conveyor belt and at the same speed. An upper heating plate(35) and a lower heating plate(25) bring an upper end rotation section of the lower conveyor belt and a lower end rotation section of the upper conveyor belt into contact with each other. Heating wires(27,37) are installed in the upper and lower heating plates respectively. The sliced deer antler sliced by a cutter is fed on the lower conveyor belt and is interposed between the upper and lower conveyor belts to pass between the upper heating plate and the lower heating plate.
Procedure for preparing triazene compounds r- = -N- = oh, where r represents a radical alkyl, alkenyl or aril, and its pharmaceutically acceptable salts. Understand the following stages: 1. Make reaction right, where r has the significance already indicated, with hydrazine in a solvent, such as alcohol, organic acid or an analogue solvent, at ambient temperature. 2. React the product resulting from the first stage with a silication agent in a solvent, such as ether, chloroform, benzene, toluene or an analogue solvent, at ambient temperature. 3. The product obtained in the second stage has been reacted with a nitroating agent in a solvent, such as dichloromethane, chloroform, carbon tetracloride, ether or an analogue solvent, at temperature below the environment, and last, the composite searched and obtained in the third stage is isolated and purifies through recristalization. The salts, pharmaceutically acceptable, are obtained by treating the product formed in the third stage with an organic or inorganic base. For use in the treatment of cardiovascular affections, bronchal dolences and hypertension. (Machine-translation by Google Translate, not legally binding)
Prospective, open-label, non-controlled, multi-center Phase 2 Study evaluating the efficacy and safety of the 10 mL BLVR System in patients with advanced upper lobe predominant emphysema. Twenty patients will be divided into 2 groups of 10 patients each and treated under conscious sedation at a total of 8 subsegments. Group 1 will be treated in 4 subsegments in 1 lung and have a second treatment of 4 subsegments in the other lung 6 to 12 weeks later. Group 2 will receive treatment at 8 subsegments (4 in each lung) during a single treatment session if possible; if not completed in 1 session the remaining subsegments will be treated 6 to 12 weeks later. Patients will be followed 96 weeks after completion of the final BLVR treatment. All patients will receive standard medical therapy in addition to BLVR treatment.
This is a non-randomized, open-label, single arm, single center, phase II clinical trial. Patients received neoadjuvant chemotherapy with cisplatin (50 mg/m2, intravenous \[IV\], day 1) in combination with doxorubicin (50 mg/m2, IV, day 1) and cyclophosphamide (500 mg/m2, IV, day 1) every 21 days and for a total of 6 cycles (CAP regimen). Subsequent mastectomy plus axillary lymph node dissection was performed. Pathological specimen was analyzed to assess tumor response in the breast and axilla. Adjuvant chemotherapy consisting of docetaxel (75 mg/m2, IV) every 21 days was further provided for 4 cycles. In case of tumor progression during neoadjuvant treatment, CAP was discontinued and additional local or systemic treatment was provided at the discretion of the investigator. The protocol was approved by the institutional review board of National Cancer Institute - Brazil. All patients provided written informed consent. The Brazilian Group of Breast Cancer Studies (GBECAM) and National Cancer Institute -Brazil were the academic sponsors and National Cancer Institute- Brazil was the funding source of the trial.
Sepsis is a syndrome of systemic inflammatory response resulting from infection, which can lead to severe lung injury. Histone deacetylase 4 (HDAC4) is a key protein known to regulate a wide range of cellular processes. This study was designed to investigate the role of HDAC4 in lipopolysaccharide (LPS)-induced alveolar epithelial cell injury as well as to disclose its potential molecular mechanisms. The alveolar epithelial cell injury model was established by inducing A549 cells with LPS. A549 cell viability was detected by cell counting kit-8 assay and the transfection efficiency of small interfering RNA targeting HDAC4 was appraised utilizing Western blot. The levels of inflammatory cytokines and oxidative stress markers were detected using corresponding assay kits. Dichloro-dihydro-fluorescein diacetate assay was used for the measurement of reactive oxygen species (ROS) content. Flow cytometry, 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethyl-benzimidazolyl-carbocyanine iodide-1 staining, adenosine triphosphate (ATP) assay kits, and MitoSOX Red assay kits were employed to estimate cell apoptosis, mitochondrial membrane potential, ATP level, and mitochondrial ROS level, respectively. The oxygen consumption rate of A549 cells was evaluated with XF96 extracellular flux analyzer. Western blot was applied for the evaluation of HDAC4, apoptosis- and c-Jun N-terminal kinase (JNK)/activating protein-1 (AP-1) signaling pathway-related proteins. HDAC4 expression was found to be increased in LPS-induced A549 cells and HDAC4 silence inhibited inflammatory damage, repressed oxidative stress, alleviated cell apoptosis, improved mitochondrial function, and blocked JNK/AP-1 signaling in A549 cells stimulated by LPS, which were all reversed by JNK activator anisomycin. Collectively, the interference with HDAC4 could ameliorate LPS-induced alveolar epithelial cell injury, and such protective effect may be potentially mediated through the JNK/AP-1 signaling pathway.
BACKGROUND: Risk stratification and population management strategies are critical for providing effective and equitable care for the growing population of older adults in the USA. Both frailty and neighborhood disadvantage are constructs that independently identify populations with higher healthcare utilization and risk of adverse outcomes.
OBJECTIVE: To examine the joint association of these factors on acute healthcare utilization using two pragmatic measures based on structured data available in the electronic health record (EHR).
DESIGN: In this retrospective observational study, we used EHR data to identify patients aged ≥ 65 years at Atrium Health Wake Forest Baptist on January 1, 2019, who were attributed to affiliated Accountable Care Organizations. Frailty was categorized through an EHR-derived electronic Frailty Index (eFI), while neighborhood disadvantage was quantified through linkage to the area deprivation index (ADI). We used a recurrent time-to-event model within a Cox proportional hazards framework to examine the joint association of eFI and ADI categories with healthcare utilization comprising emergency visits, observation stays, and inpatient hospitalizations over one year of follow-up.
KEY RESULTS: We identified a cohort of 47,566 older adults (median age = 73, 60% female, 12% Black). There was an interaction between frailty and area disadvantage (P = 0.023). Each factor was associated with utilization across categories of the other. The magnitude of frailty's association was larger than living in a disadvantaged area. The highest-risk group comprised frail adults living in areas of high disadvantage (HR 3.23, 95% CI 2.99-3.49; P < 0.001). We observed additive effects between frailty and living in areas of mid- (RERI 0.29; 95% CI 0.13-0.45; P < 0.001) and high (RERI 0.62, 95% CI 0.41-0.83; P < 0.001) neighborhood disadvantage.
CONCLUSIONS: Considering both frailty and neighborhood disadvantage may assist healthcare organizations in effectively risk-stratifying vulnerable older adults and informing population management strategies. These constructs can be readily assessed at-scale using routinely collected structured EHR data.
1445831 Iron and aluminium derivatives of glycyrrhizinic acid L R BOISSEVAIN 7 Aug 1973 [22 Aug 1972] 13455/72 Heading C2U [Also in Division A5] An iron or aluminium derivative of glycyrrhizinic acid, in which the amount of glycyrrhizinic moieties is at least 5% by weight and in which at least two thirds of the glycyrrhizinic moieties are insoluble in water, the glycyrrhizinic moiety weight being calculated as acid, which has been prepared by heating a product containing water soluble iron or aluminium glycyrrhizinate at a temperature of at least 70‹ C. for a sufficient time for the solubility to be reduced to the desired amount is novel. Preferably an aqueous soln. of iron or aluminium glycyrrhizinate is evaporated and optionally subsequently baked. The solution may be obtained by including active iron or aluminium in a solution of the free acid, digesting the solids therein with water for at least 12 hours and separating the solids from the solution. The solution of the acid may suitably be derived from liquorice. The product has anti-inflammatory and histiogenic properties and may be made up into pharmaceutical compositions.
[GB1445831A]